Статья
ГАСТРОЭНТЕРОПАТИИ, СВЯЗАННЫЕ С ПРИЕМОМ АЦЕТИЛСАЛИЦИЛОВОЙ КИСЛОТЫ: КАК ПОВЫСИТЬ БЕЗОПАСНОСТЬ ЛЕЧЕНИЯ
Повреждение слизистой оболочки желудочно-кишечного тракта является основным фактором, ограничивающим использование ацетилсалициловой кислоты (АСК) у больных атеротромбозом. На сегодняшний день самым доступным способом, позволяющим снизить риск желудочно-кишечных осложнений, остается прием АСК в минимально эффективной дозе, не превышающей 75-81 мг/сут. По возможности следует избегать сочетанного применения АСК с другими антиагрегантами, антикоагулянтами, нестероидными противовоспалительными препаратами и кортикостероидами. Рутинное назначение противоязвенной терапии у больных, получающих АСК, не показано в связи с недостатком клинических исследований, подтверждающих эффективность такой тактики. При наличии высокого риска серьезных осложнений рекомендуется эрадикация H. pylori в сочетании с длительной профилактической терапией ингибиторами желудочной секреции, среди которых отдавать предпочтение следует ингибиторам протонной помпы.
1. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310(6983):827-30.
2. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343(12):834-9.
3. McDowell A., Engel A., Massey J.T., Maurer K. Plan and operation of the Second National Health and Nutrition Examination Survey, 1976-1980. Vital Health Stat 1. 1981;(15):1-144.
4. Collaborative meta analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ 2002;324:71–86.
5. Беленков Ю.Н., Панченко Е.П. Характеристика и исходы атеротромбоза у амбулаторных больных в Российской Федерации (по материалам международного регистра REACH). Кардиология 2008;48(2):17-24
6. Bhatt D.L., Steg P.G., Ohman E.M. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA;2006;295:180-9.
7. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Anti�platelet Therapy and NSAID Use. J Am Coll Cardiol 2008;52(18):1502–17.
8. Becker J.S., Domschke W., Pohle T. Current approaches to prevent NSAID-induced gastropathy – COX selectivity and beyond. Br J Clin Pharmacol 2004;58(6):587–600
9. Cryer B. Gastrointestinal safety of low-dose aspirin. Am J Manag Care. 2002;8(22 Suppl):S701-8.
10. Chan F.K., Graham D.Y. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004;19:1051–61.
11. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359(9300):14-22.
12. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310(6983):827-30.
13. Каратеев А.Е. Лечение и медикаментозная профилактика НПВП-гастропатии: основные по- ложения. Фарматека 2006, 6 (121):37-45
14. Olivero J.J., Graham D.Y. Gastric adaptation to nonsteroidal anti-inflammatory drugs in man. Scand J Gastroenterol Suppl. 1992;193:53-8.
15. Ofman J.J., Maclean C.H., Straus W.L., et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2003;49(4):508-18.
16. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105(1B):31S–38S.
17. Wolfe M., Lichtenstein D., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888–99.
18. Lanas A., Perez-Aisa M., Feu F., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005;100:1685–93.
19. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal compli�cations in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A ran�domized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241–9.
20. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what’s the risk? Aliment Pharmacol Ther 2006;24:897–908.
21. Sorensen H.T., Mellemkjaer L., Blot W.J., et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000;95:2218-24.
22. Cryer B., Cung A.D., Kelly K.C., Weideman R. Risks of diverticular bleeding with NSAIDs and low-dose aspirin. Gastroenterology. 2002;122:87.
23. Patrono C., Bachmann F., Baigent C., et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004;25(2):166-81.
24. Patrono C., Baigent C., Hirsh J., Roth G.; American College of Chest Physicians. Antiplatelet Drugs. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):199S–233S.
25. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827-30.
26. Henry D., Dobson A., Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993;105:1078-88.
27. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–304.
28. Hoftiezer J.W., Silvoso G.R., Burks M., Ivey K.J. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet 1980;2:609–12.
29. Lanza F.L., Royer G.L. Jr., Nelson R.S. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980;303:136–38.
30. Hawthorne A.B., Mahida Y.R., Cole A.T., Hawkey C.J. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991;32:77– 83.
31. Gilman A.G., Rall T.W., Nies A.S., eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 8th ed. New York: Pergamon Press, 1990.
32. Kelly J.P., Kaufman D.W., Jurgelon J.M., et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413–16.
33. Garca Rodrguez L.A., Hern�ndez-Daz S., de Abajo F.J. Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies. Br J Clin Pharmacol 2001;52:563-71.
34. Janssen M., Dijkmans B.A., Vandenbroucke J.P., et al. Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use. Dig Dis Sci 1994;39:362–5.
35. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;(4):CD002296.
36. Silverstein F.E., Graham D.Y., Senior J.R. et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241–9.
37. Graham D.Y., Agrawal N.M., Campbell D.R. et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002;162:169–75.
38. Singh G., Ramey D.R., Morfeld D., Shi H., Hatoum H.T., Fries J.F. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530–6.
39. Yeomans N.D., Tulassay Z., Juhsz L., et al. A comparison of omeprazole with ranitidine for ulcers as�sociated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338: 719-26.
40. Pilotto A., Franceschi M., Leandro G. et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004;20:1091–7.
41. Wilder-Smith C.H., Rohss K., Nilsson-Pieschl C., et al. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoparzole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion 2003;68:184–8.
42. Laine L. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Disord 2003;3 Suppl 4:S30–9.
43. Yeomans N.D., Hawkey C.J., Jones R. et al. Esomeprazole provides effective control of NSAID-associated upper GI symptoms in patients continuing to take NSAIDs (abstract). Gastroenterology 2003;124 (Suppl. 1):A107.
44. Sung J., Lau J., Ching J., et al. Can aspirin be reintroduced with PPI inhibitor INFUSION after endoscopic hemostatis: a double-blinded randomized controlled trial (abstract). Gastroenterology. 2008;130:A44.
45. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non- ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-STElevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1–157.
46. Chan F., Ching J., Hung L., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238–44.
47. Lai K., Chu K., Hui W., et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006;4:860–5.
48. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731–8.
49. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet.1996;348:1329–39.